Xencor Stock Price, News & Analysis (NASDAQ:XNCR)

$27.64 +1.25 (+4.74 %)
(As of 02/25/2018 08:22 AM ET)
Previous Close$27.64
Today's Range$24.90 - $27.90
52-Week Range$18.55 - $28.64
Volume227,509 shs
Average Volume171,382 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97

About Xencor (NASDAQ:XNCR)

Xencor logoXencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900

Debt

Debt-to-Equity RatioN/A
Current Ratio2.17%
Quick Ratio2.17%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$87.52 million
Price / Sales14.83
Cash Flow$0.60 per share
Price / Cash46.00
Book Value$6.87 per share
Price / Book4.02

Profitability

Trailing EPS($1.00)
Net Income$23.62 million
Net Margins-148.29%
Return on Equity-15.26%
Return on Assets-11.11%

Miscellaneous

Employees83
Outstanding Shares46,960,000

Xencor (NASDAQ:XNCR) Frequently Asked Questions

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) posted its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $1.31. The biopharmaceutical company had revenue of $66 million for the quarter, compared to analysts' expectations of $7.43 million. Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%. View Xencor's Earnings History.

Where is Xencor's stock going? Where will Xencor's stock price be in 2018?

6 equities research analysts have issued 12-month target prices for Xencor's shares. Their predictions range from $21.00 to $36.00. On average, they expect Xencor's share price to reach $30.80 in the next year. View Analyst Ratings for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:

  • 1. Cantor Fitzgerald analysts commented, "XNCR announced initiation of a Phase 1 trial of XmAb18087 in subjects with neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)." (2/22/2018)
  • 2. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (2/20/2018)
  • 3. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)

Who are some of Xencor's key competitors?

Who are Xencor's key executives?

Xencor's management team includes the folowing people:

  • Bassil I. Dahiyat Ph.D., President, Chief Executive Officer, Founder, Director (Age 46)
  • John R Desjarlais, Senior Vice President, Research and Chief Scientific Officer (Age 52)
  • Paul Foster M.D., Senior Vice President, Chief Medical Officer (Age 63)
  • John J. Kuch, Vice President - Finance (Age 57)
  • Edgardo Baracchini Jr. Ph.D., Chief Business Officer (Age 57)
  • A. Bruce Montgomery M.D., Lead Independent Director (Age 63)
  • Richard J. Ranieri, Director (Age 62)
  • Kevin C. Gorman Ph.D., Independent Director (Age 58)
  • Kurt A. Gustafson, Independent Director (Age 49)
  • Yujiro S. Hata, Independent Director (Age 43)

Who owns Xencor stock?

Xencor's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.64%), Redmile Group LLC (2.88%), Perceptive Advisors LLC (2.80%), ArrowMark Colorado Holdings LLC (1.24%), Franklin Resources Inc. (1.15%) and Geode Capital Management LLC (0.75%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Who sold Xencor stock? Who is selling Xencor stock?

Xencor's stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, BlackRock Inc., TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, Falcon Point Capital LLC, Metropolitan Life Insurance Co. NY and Rhumbline Advisers. Company insiders that have sold Xencor company stock in the last year include Bruce L A Carter, Edgardo Baracchini Jr, John J Kuch and Paul A Foster. View Insider Buying and Selling for Xencor.

Who bought Xencor stock? Who is buying Xencor stock?

Xencor's stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, ArrowMark Colorado Holdings LLC, Deutsche Bank AG, Millennium Management LLC, Two Sigma Investments LP, Renaissance Technologies LLC, Macquarie Group Ltd. and Perceptive Advisors LLC. View Insider Buying and Selling for Xencor.

How do I buy Xencor stock?

Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of Xencor stock can currently be purchased for approximately $27.64.

How big of a company is Xencor?

Xencor has a market capitalization of $1.30 billion and generates $87.52 million in revenue each year. The biopharmaceutical company earns $23.62 million in net income (profit) each year or ($1.00) on an earnings per share basis. Xencor employs 83 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]


MarketBeat Community Rating for Xencor (XNCR)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Xencor (NASDAQ:XNCR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.602.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.80$30.80$30.25$29.40
Price Target Upside: 22.56% upside54.00% upside43.84% upside26.23% upside

Xencor (NASDAQ:XNCR) Consensus Price Target History

Price Target History for Xencor (NASDAQ:XNCR)

Xencor (NASDAQ:XNCR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Cantor FitzgeraldInitiated CoverageBuy$33.00LowView Rating Details
11/12/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00N/AView Rating Details
10/23/2017Canaccord GenuitySet Price TargetBuy$36.00N/AView Rating Details
6/16/2017WedbushReiterated RatingOutperform$29.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$21.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$26.00N/AView Rating Details
5/2/2016OppenheimerReiterated RatingBuyN/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Xencor (NASDAQ:XNCR) Earnings History and Estimates Chart

Earnings by Quarter for Xencor (NASDAQ:XNCR)

Xencor (NASDAQ XNCR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.29)($0.33)$8.15 million$7.00 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.25)($0.15)$8.15 million$13.34 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.31)$8.15 million$4.34 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.33)($0.21)$7.65 million$6.44 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.19)($0.20)$15.65 million$7.82 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)$1.13$7.43 million$66.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.27)($0.16)$3.50 million$7.30 millionViewN/AView Earnings Details
3/7/2016Q415($0.30)$0.19$2.50 million$21.80 millionViewN/AView Earnings Details
11/3/2015Q315($0.17)($0.25)$3.57 million$3.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.18)($0.22)$1.90 million$1.01 millionViewN/AView Earnings Details
5/4/2015Q115($0.17)($0.19)$1.90 million$1.49 millionViewListenView Earnings Details
2/19/2015($0.22)($0.04)$1.33 million$5.66 millionViewN/AView Earnings Details
11/10/2014Q3 14($0.19)($0.20)$1.50 million$0.85 millionViewN/AView Earnings Details
7/31/2014($0.19)($0.16)$0.82 millionViewN/AView Earnings Details
5/14/2014Q1 14($0.16)($0.12)$1.71 million$2.20 millionViewN/AView Earnings Details
3/19/2014Q413($0.14)($0.24)$1.71 million$1.70 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Xencor (NASDAQ:XNCR) Earnings Estimates

2018 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.43)($0.43)($0.43)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.48)($0.48)($0.48)
Q4 20181($0.47)($0.47)($0.47)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Xencor (NASDAQ:XNCR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Xencor (NASDAQ XNCR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 77.11%
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)
Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Xencor (NASDAQ XNCR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2018Paul A FosterInsiderSell10,000$26.03$260,300.0012,419View SEC Filing  
2/16/2018Paul A FosterInsiderSell5,000$25.01$125,050.007,419View SEC Filing  
12/14/2017John S Stafford IIIMajor ShareholderBuy9,215$20.76$191,303.40View SEC Filing  
12/12/2017John S Stafford IIIMajor ShareholderBuy6,215$20.72$128,774.80View SEC Filing  
11/28/2017John S Stafford IIIMajor ShareholderBuy15,374$19.86$305,327.64View SEC Filing  
11/24/2017John S Stafford IIIMajor ShareholderBuy5,349$19.85$106,177.65View SEC Filing  
11/10/2017John S Stafford IIIMajor ShareholderBuy324$19.90$6,447.60View SEC Filing  
11/8/2017John S Stafford IIIMajor ShareholderBuy3,400$19.89$67,626.00View SEC Filing  
11/6/2017John S Stafford IIIMajor ShareholderBuy305$19.92$6,075.60View SEC Filing  
11/2/2017John S Stafford IIIMajor ShareholderBuy50,000$19.58$979,000.00View SEC Filing  
10/31/2017John S Stafford IIIMajor ShareholderBuy13,700$19.81$271,397.00View SEC Filing  
10/27/2017John S Stafford IIIMajor ShareholderBuy150,000$19.81$2,971,500.00View SEC Filing  
10/25/2017John S Stafford IIIMajor ShareholderBuy24,653$20.01$493,306.53View SEC Filing  
8/22/2017John S Stafford IIIMajor ShareholderBuy41,016$19.69$807,605.04View SEC Filing  
8/18/2017John S Stafford IIIMajor ShareholderBuy43,500$19.93$866,955.00View SEC Filing  
8/17/2017John S Stafford IIIMajor ShareholderBuy79,035$20.47$1,617,846.45View SEC Filing  
8/16/2017John S Stafford IIIMajor ShareholderBuy25,000$20.96$524,000.00View SEC Filing  
8/11/2017John S Stafford IIIMajor ShareholderBuy27,000$21.13$570,510.00View SEC Filing  
6/28/2017John S Stafford IIIMajor ShareholderBuy6,000$19.94$119,640.00View SEC Filing  
6/16/2017John S Stafford IIIMajor ShareholderBuy1,500$19.67$29,505.00View SEC Filing  
6/14/2017Bruce L A CarterDirectorSell20,000$20.61$412,200.0048,880View SEC Filing  
6/2/2017Bruce L A CarterDirectorSell2,366$22.00$52,052.0068,578View SEC Filing  
5/26/2017Bruce L A CarterDirectorSell12,400$22.19$275,156.0083,344View SEC Filing  
5/2/2017Edgardo Baracchini JrInsiderSell10,568$26.01$274,873.689,818View SEC Filing  
4/27/2017Edgardo Baracchini JrInsiderSell904$26.04$23,540.16904View SEC Filing  
3/16/2017John J. KuchVPSell15,000$24.42$366,300.00View SEC Filing  
3/8/2017Edgardo Baracchini JrInsiderSell1,821$25.00$45,525.001,821View SEC Filing  
12/6/2016John S Stafford IIIMajor ShareholderSell63,061$27.71$1,747,420.31View SEC Filing  
9/28/2016Edgardo Baracchini JrInsiderSell10,000$25.35$253,500.0010,000View SEC Filing  
9/27/2016John S Stafford IIIMajor ShareholderSell40,000$25.72$1,028,800.00View SEC Filing  
9/2/2016Edgardo Baracchini JrInsiderSell10,000$21.06$210,600.0010,000View SEC Filing  
8/30/2016Bassil I DahiyatInsiderSell40,000$21.80$872,000.00341,128View SEC Filing  
8/26/2016John S Stafford IIIMajor ShareholderSell24,351$21.48$523,059.48View SEC Filing  
8/24/2016John J KuchVPSell25,000$21.95$548,750.0092,078View SEC Filing  
8/23/2016John R DesjarlaisVPSell16,294$21.73$354,068.6228,640View SEC Filing  
8/23/2016John S Stafford IIIMajor ShareholderSell96,828$21.73$2,104,072.44View SEC Filing  
8/16/2016Bassil I DahiyatInsiderSell45,886$22.06$1,012,245.16365,321View SEC Filing  
8/15/2016Bruce L A CarterDirectorSell3,400$22.67$77,078.0010,000View SEC Filing  
8/15/2016John S Stafford IIIMajor ShareholderSell10,000$23.06$230,600.00View SEC Filing  
8/11/2016John S Stafford IIIMajor ShareholderSell30,500$21.87$667,035.007,500View SEC Filing  
8/10/2016Edgardo Baracchini JrInsiderSell2,500$21.83$54,575.002,500View SEC Filing  
8/3/2016Edgardo Baracchini, Jr.InsiderSell4,528$20.00$90,560.00View SEC Filing  
8/3/2016John R. DesjarlaisVPSell5,905$20.00$118,100.00View SEC Filing  
7/11/2016Edgardo Baracchini JrInsiderSell1,250$18.13$22,662.505,778View SEC Filing  
6/28/2016Edgardo Baracchini JrInsiderSell1,250$15.10$18,875.005,778View SEC Filing  
5/24/2016Bassil I DahiyatCEOSell45,886$13.00$596,518.00358,186View SEC Filing  
4/7/2016Edgardo Baracchini JrInsiderSell3,750$15.00$56,250.008,278View SEC Filing  
3/17/2016Bassil I DahiyatCEOSell45,886$11.02$505,663.72289,358View SEC Filing  
3/3/2016John R DesjarlaisVPSell14,260$12.01$171,262.6057,709View SEC Filing  
2/1/2016John S Stafford IIIMajor ShareholderSell25$10.79$269.755,264,740View SEC Filing  
1/29/2016John S Stafford IIIMajor ShareholderBuy25$10.83$270.755,264,740View SEC Filing  
1/4/2016John R. DesjarlaisVPSell1,100$14.13$15,543.0027,323View SEC Filing  
12/17/2015John J KuchVPSell4,781$14.89$71,189.0910,650View SEC Filing  
12/16/2015Paul A. FosterinsiderSell6,025$15.01$90,435.253,602View SEC Filing  
12/3/2015John S. Stafford IIIDirectorSell30,000$15.13$453,900.005,264,740View SEC Filing  
11/25/2015Edgardo Baracchini, Jr.insiderSell2,500$15.00$37,500.00View SEC Filing  
9/3/2015John S Stafford IIIDirectorSell10,000$17.22$172,200.0077,500View SEC Filing  
9/1/2015Edgardo Baracchini, Jr.insiderSell1,250$16.49$20,612.50View SEC Filing  
7/6/2015John S Stafford IIIDirectorSell10,000$22.29$222,900.00View SEC Filing  
7/1/2015Edgardo Baracchini JrInsiderSell2,500$22.24$55,600.00View SEC Filing  
6/16/2015John S Stafford IIIDirectorSell20,000$20.35$407,000.00View SEC Filing  
6/15/2015Bruce L A CarterDirectorSell10,000$19.21$192,100.00View SEC Filing  
6/15/2015Edgardo Baracchini JrInsiderSell1,277$19.85$25,348.45View SEC Filing  
6/12/2015John J KuchVPSell8,756$19.35$169,428.60View SEC Filing  
6/12/2015John S Stafford IIIDirectorSell250,000$19.00$4,750,000.00View SEC Filing  
6/3/2015John S Stafford IIIDirectorSell10,000$18.76$187,600.00View SEC Filing  
6/1/2015Edgardo Baracchini JrInsiderSell1,250$18.14$22,675.00View SEC Filing  
5/26/2015John S Stafford IIIDirectorSell10,000$17.01$170,100.00View SEC Filing  
5/15/2015Edgardo Baracchini JrInsiderSell1,604$15.00$24,060.00View SEC Filing  
8/11/2014John S Stafford IIIDirectorSell124,000$9.37$1,161,880.00View SEC Filing  
12/6/2013John S Stafford IIIDirectorBuy275,000$5.50$1,512,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Xencor (NASDAQ XNCR) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Xencor Inc (XNCR) to Announce -$0.27 EPS Brokerages Anticipate Xencor Inc (XNCR) to Announce -$0.27 EPS
www.americanbankingnews.com - February 24 at 8:06 AM
Xencor Inc (XNCR) Insider Sells $260,300.00 in StockXencor Inc (XNCR) Insider Sells $260,300.00 in Stock
www.americanbankingnews.com - February 22 at 9:38 PM
Cantor Fitzgerald Initiates Coverage on Xencor (XNCR)Cantor Fitzgerald Initiates Coverage on Xencor (XNCR)
www.americanbankingnews.com - February 22 at 4:24 PM
Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal TumorsXencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors
finance.yahoo.com - February 22 at 8:47 AM
Xencor (XNCR) Stock Rating Upgraded by Zacks Investment ResearchXencor (XNCR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 20 at 4:50 PM
Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018
finance.yahoo.com - February 20 at 8:39 AM
Xencor (XNCR) Raised to Hold at BidaskClubXencor (XNCR) Raised to Hold at BidaskClub
www.americanbankingnews.com - February 17 at 9:22 PM
Paul A. Foster Sells 5,000 Shares of Xencor Inc (XNCR) StockPaul A. Foster Sells 5,000 Shares of Xencor Inc (XNCR) Stock
www.americanbankingnews.com - February 16 at 10:02 PM
Xencor Inc (XNCR) Receives Average Rating of "Hold" from AnalystsXencor Inc (XNCR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 10 at 1:48 AM
Xencor Inc (XNCR) Expected to Announce Quarterly Sales of $15.65 MillionXencor Inc (XNCR) Expected to Announce Quarterly Sales of $15.65 Million
www.americanbankingnews.com - February 9 at 6:02 AM
-$0.27 EPS Expected for Xencor Inc (XNCR) This Quarter-$0.27 EPS Expected for Xencor Inc (XNCR) This Quarter
www.americanbankingnews.com - February 7 at 11:56 AM
Xencor (XNCR) Stock Rating Upgraded by BidaskClubXencor (XNCR) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 28 at 11:22 PM
 Analysts Anticipate Xencor Inc (XNCR) Will Announce Earnings of -$0.27 Per Share Analysts Anticipate Xencor Inc (XNCR) Will Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - January 21 at 9:16 AM
Xencor (XNCR) Stock Rating Reaffirmed by Zacks Investment ResearchXencor (XNCR) Stock Rating Reaffirmed by Zacks Investment Research
www.americanbankingnews.com - January 13 at 2:42 PM
Contrasting Lexicon Pharmaceuticals (LXRX) and Xencor (XNCR)Contrasting Lexicon Pharmaceuticals (LXRX) and Xencor (XNCR)
www.americanbankingnews.com - January 8 at 5:06 PM
Xencor (XNCR) Announces 2018 Priorities, Expected MilestonesXencor (XNCR) Announces 2018 Priorities, Expected Milestones
www.streetinsider.com - January 6 at 4:24 PM
 Analysts Expect Xencor Inc (XNCR) Will Post Quarterly Sales of $15.65 Million Analysts Expect Xencor Inc (XNCR) Will Post Quarterly Sales of $15.65 Million
www.americanbankingnews.com - January 6 at 5:02 AM
Xencor Announces 2018 Priorities and Expected MilestonesXencor Announces 2018 Priorities and Expected Milestones
finance.yahoo.com - January 5 at 10:45 AM
FY2019 Earnings Forecast for Xencor Inc Issued By Cantor Fitzgerald (XNCR)FY2019 Earnings Forecast for Xencor Inc Issued By Cantor Fitzgerald (XNCR)
www.americanbankingnews.com - January 5 at 12:08 AM
 Analysts Expect Xencor Inc (XNCR) to Announce -$0.27 EPS Analysts Expect Xencor Inc (XNCR) to Announce -$0.27 EPS
www.americanbankingnews.com - January 4 at 1:30 PM
Commit To Purchase Xencor At $15, Earn 10.7% Annualized Using OptionsCommit To Purchase Xencor At $15, Earn 10.7% Annualized Using Options
www.nasdaq.com - January 2 at 5:09 PM
ETFs with exposure to Xencor, Inc. : December 28, 2017ETFs with exposure to Xencor, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:21 PM
Xencor, Inc. :XNCR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Xencor, Inc. :XNCR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:14 PM
Xencor, Inc. (XNCR) Receives Consensus Rating of "Hold" from AnalystsXencor, Inc. (XNCR) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 22 at 1:34 AM
Xencor, Inc. (XNCR) Expected to Post Quarterly Sales of $15.65 MillionXencor, Inc. (XNCR) Expected to Post Quarterly Sales of $15.65 Million
www.americanbankingnews.com - December 21 at 3:00 PM
FY2017 EPS Estimates for Xencor, Inc. (XNCR) Lifted by WedbushFY2017 EPS Estimates for Xencor, Inc. (XNCR) Lifted by Wedbush
www.americanbankingnews.com - December 21 at 8:00 AM
Xencor (XNCR) Names Richard Ranieri to BoardXencor (XNCR) Names Richard Ranieri to Board
www.streetinsider.com - December 19 at 10:36 AM
Xencor Appoints Richard Ranieri to Board of DirectorsXencor Appoints Richard Ranieri to Board of Directors
finance.yahoo.com - December 19 at 10:36 AM
-$0.34 EPS Expected for Xencor, Inc. (XNCR) This Quarter-$0.34 EPS Expected for Xencor, Inc. (XNCR) This Quarter
www.americanbankingnews.com - December 19 at 1:26 AM
BidaskClub Downgrades Xencor (XNCR) to Strong SellBidaskClub Downgrades Xencor (XNCR) to Strong Sell
www.americanbankingnews.com - December 16 at 11:26 AM
Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 6,215 Shares of StockInsider Buying: Xencor, Inc. (XNCR) Major Shareholder Purchases 6,215 Shares of Stock
www.americanbankingnews.com - December 14 at 6:26 PM
Xencor, Inc. (XNCR) Major Shareholder Buys $191,303.40 in StockXencor, Inc. (XNCR) Major Shareholder Buys $191,303.40 in Stock
www.americanbankingnews.com - December 14 at 5:58 PM
Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : December 14, 2017Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : December 14, 2017
finance.yahoo.com - December 14 at 4:55 PM
Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : December 13, 2017Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : December 13, 2017
finance.yahoo.com - December 13 at 10:54 AM
Xencor (XNCR) Lifted to Sell at BidaskClubXencor (XNCR) Lifted to Sell at BidaskClub
www.americanbankingnews.com - December 8 at 12:38 AM
Xencor Receives Milestone Payment from AmgenXencor Receives Milestone Payment from Amgen
finance.yahoo.com - December 5 at 12:17 PM
 Brokerages Expect Xencor, Inc. (XNCR) Will Announce Quarterly Sales of $10.65 Million Brokerages Expect Xencor, Inc. (XNCR) Will Announce Quarterly Sales of $10.65 Million
www.americanbankingnews.com - December 2 at 2:24 AM
Xencor (XNCR) & Aeglea Bio Therapeutics (AGLE) Critical ReviewXencor (XNCR) & Aeglea Bio Therapeutics (AGLE) Critical Review
www.americanbankingnews.com - December 1 at 3:34 PM
Zacks: Brokerages Expect Xencor, Inc. (XNCR) to Announce -$0.34 Earnings Per ShareZacks: Brokerages Expect Xencor, Inc. (XNCR) to Announce -$0.34 Earnings Per Share
www.americanbankingnews.com - November 30 at 9:32 PM
Xencor (XNCR) Receives New Coverage from Analysts at Cantor FitzgeraldXencor (XNCR) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - November 29 at 9:35 AM
Xencor, Inc. (XNCR) Major Shareholder Purchases $106,177.65 in StockXencor, Inc. (XNCR) Major Shareholder Purchases $106,177.65 in Stock
www.americanbankingnews.com - November 28 at 7:54 PM
Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Acquires 15,374 Shares of StockInsider Buying: Xencor, Inc. (XNCR) Major Shareholder Acquires 15,374 Shares of Stock
www.americanbankingnews.com - November 28 at 7:52 PM
Contrasting Intercept Pharmaceuticals (ICPT) & Xencor (XNCR)Contrasting Intercept Pharmaceuticals (ICPT) & Xencor (XNCR)
www.americanbankingnews.com - November 28 at 3:06 PM
Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : November 27, 2017Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : November 27, 2017
finance.yahoo.com - November 27 at 8:18 AM
Xencor, Inc. (XNCR) Given Average Rating of "Hold" by BrokeragesXencor, Inc. (XNCR) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
Xencor Inc. (XNCR) Is Losing Ground In Early TradeXencor Inc. (XNCR) Is Losing Ground In Early Trade
www.rttnews.com - November 24 at 6:37 PM
Xencor, Inc. (XNCR) Raised to "Hold" at Zacks Investment ResearchXencor, Inc. (XNCR) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 22 at 8:16 AM
Head-To-Head Contrast: Xencor (XNCR) vs. Its CompetitorsHead-To-Head Contrast: Xencor (XNCR) vs. Its Competitors
www.americanbankingnews.com - November 17 at 3:30 PM
Xencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 3,400 SharesXencor, Inc. (XNCR) Major Shareholder John S. Stafford III Purchases 3,400 Shares
www.americanbankingnews.com - November 13 at 6:26 PM
Xencor, Inc. (XNCR) Stock Rating Reaffirmed by Piper Jaffray CompaniesXencor, Inc. (XNCR) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - November 13 at 2:29 PM

SEC Filings

Xencor (NASDAQ:XNCR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Xencor (NASDAQ:XNCR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Xencor (NASDAQ XNCR) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.